Your session is about to expire
← Back to Search
Recombinant hepatitis B vaccine with CpG adjuvant for Hepatitis B Vaccine Nonresponder
Study Summary
This trial is testing a new hepatitis B vaccine to see if it works better than the current one for people who didn't respond to the current one.
- Healthcare Worker Hepatitis B Vaccine Nonresponder
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are participants currently being accepted for this trial?
"Clinicaltrials.gov indicates that this trial is currently recruiting participants, the posting having initially been made on September 15th 2020 with a last update occurring on September 12th 2022."
What is the maximum capacity for enrollees in this medical research?
"Affirmative. According to clinicaltrials.gov, this medical study is currently seeking participants; first posted September 15th 2020 and was last revised on September 12th 2022. 130 individuals need to be enrolled from a single trial site."
Has the recombinant hepatitis B vaccine with CpG adjuvant earned FDA approval?
"The recombinant hepatitis b vaccine combined with CpG adjuvant has data indicating safety and efficacy, earning it a score of 3."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger